Company profilePharmaceutical#765 of 1,318 in Pakistan10 DRAP alerts

Merixil Pharma DSL: DHO-ISB-1745

Pharmaceutical company · 11 brands · 16 molecules

11 registered products 12 pharmaceutical brands 16 distinct molecules 10 DRAP alerts

Company overview

11
registered products
12
pharmaceutical brands
16
distinct molecules
0
therapeutic classes
10
DRAP alerts

Merixil Pharma DSL: DHO-ISB-1745 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 11 product registrations across 16 distinct molecules. DRAP has issued 87 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Merixil

16 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

15
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202615

Top molecules by brand count

Leuprorelin ...... 22.5 Mg1 brand
Voriconazole ...... 200 Mg1 brand
Bendamustine ...... 100 Mg1 brand
Docetaxel ...... 80 Mg1 brand
Docetaxel ...... 20 Mg1 brand
Docetaxel1 brand
Paclitaxel ...... 300 Mg1 brand
Paclitaxel1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official11 products · Rs 1,384.94 – Rs 64,630.49
DVAGO1 products · Rs 8,550 – Rs 8,550
Median across source: Rs 16,619.26

Regulatory record

10 alerts in the DRAP feed we track.

37. Rapid Alert – Falsified DARZALEX (Daratumumab) Injection
2026-07-16
35. Recall Alert – DTL Punjab Declared Substandard Drug Products.
2026-06-18
27. Rapid Alert – Falsified IMFINZI Injection & ENHERTU 100mg
2026-05-06
25. Recall Alert (Human) – CDL Declared Substandard products.
2026-05-04
24. Recall Alert – Veterinary Drug Products declared Substandard by DTL Punjab
2026-04-14
22. Recall Alert – Drug Products declared substandard by Provincial laboratories.
2026-04-14
21. Rapid Alert – SPURIOUS Nandrolone Injection 100mg/ml
2026-04-14
11. Rapid Alert – SPURIOUS & SUBSTANDARD INJECTION VENOFER 5 mL (Batch No. 4721026AA)
2026-03-11

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

000 I.UB AntigenBortezomibCarboplatinCinitapride HydrogenCisplatin
Oncogen Pharma (Pvt) Limited holds 6 molecules not in this portfolio
AbirateroneDoxorubicinImatinibLenalidomideNilotinibNilotinib Monohydrochloride Eq. To Nilotinib
Pharmasol (Pvt) Ltd. holds 111 molecules not in this portfolio
AcetazolamideAcyclovirAlpha KetoanaloguesAnastrazoleAnastrozoleAprepitant

Get the full profile for Merixil

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.